Novartis begins testing of new anti-malarial as older drug loses potency

Novartis AG began testing a new anti-malaria pill in Africa, advancing development of an alternative to its most effective treatment that billionaire philanthropist Bill Gates said risked losing potency.

Patients in Mali infected with the mosquito-borne parasite began receiving the experimental drug, known as KAF156, in combination with another medicine, the drug maker said Monday. More than 500 children and adults across nine countries in Africa and Asia will be enrolled in the mid-stage study over the next few months.

The research, being conducted with the Medicines for Malaria Venture, aims to determine the most effective and tolerable dose, and ultimately fill an unmet need for a novel treatment to stave off the development of drug-resistance. Strains of the Plasmodium falciparum parasite that evade artemisinin, the most potent malaria-killer, have been detected in five Asian countries and risk-taking hold in Africa, where there have been sporadic reports of reduced sensitivity to artemisinin-based therapies, said Vas Narasimhan, Global Head of Drug Development at Basel, Switzerland-based Novartis.

The fact that we are already able to find parasites that are starting to show resistance is a cause for concern,” Narasimhan said in an interview. “We have to get ahead of this now because we wouldn’t want to be in a situation where we lose one of those medicines to resistance on a large scale.”

Malaria kills a child every two minutes, according to the World Health Organization.

WHO said last year it was rolling out the first malaria vaccine — developed by GlaxoSmithKline Plc and the PATH Malaria Vaccine Initiative — in pilot projects in Africa with vaccinations to begin in 2018.

Novartis began selling Coartem, a combination of an artemisinin derivative and lumefantrine, in 1999. Since 2001, the drug maker has provided more than 800 million treatments of Coartem without profit in one of the health-care industry’s largest access-to-medicine programmes.

The company’s promising treatment KAF156 was among the first of a new class of malaria drugs to enter mid-stage tests in more than 20 years, Novartis said last year. It expects to complete the phase 2b study by late 2019. Narasimhan added it’s too early to say when it would reach the market.


Leave a Reply

Your email address will not be published. Required fields are marked *


    No comments found.